Cargando…

SH3YL1 Protein Predicts Renal Outcomes in Patients with Type 2 Diabetes

NADPH oxidase (NOX)-derived oxidative stress is an important factor in renal progression, with NOX4 being the predominant NOX in the kidney. Recently, Src homology 3 (SH3) domain-containing YSC84-like 1 (SH3YL1) was reported to be a regulator of NOX4. In this study, we tested whether the SH3YL1 prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sang Youb, Han, Seung Hyun, Ghee, Jung Yeon, Cha, Jin Joo, Kang, Young Sun, Cha, Dae Ryong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141384/
https://www.ncbi.nlm.nih.gov/pubmed/37109492
http://dx.doi.org/10.3390/life13040963
_version_ 1785033374740512768
author Han, Sang Youb
Han, Seung Hyun
Ghee, Jung Yeon
Cha, Jin Joo
Kang, Young Sun
Cha, Dae Ryong
author_facet Han, Sang Youb
Han, Seung Hyun
Ghee, Jung Yeon
Cha, Jin Joo
Kang, Young Sun
Cha, Dae Ryong
author_sort Han, Sang Youb
collection PubMed
description NADPH oxidase (NOX)-derived oxidative stress is an important factor in renal progression, with NOX4 being the predominant NOX in the kidney. Recently, Src homology 3 (SH3) domain-containing YSC84-like 1 (SH3YL1) was reported to be a regulator of NOX4. In this study, we tested whether the SH3YL1 protein could predict 3-year renal outcomes in patients with type 2 diabetes. A total of 131 patients with type 2 diabetes were enrolled in this study. Renal events were defined as a 15% decline in the estimated glomerular filtration rate (eGFR) from the baseline, the initiation of renal replacement therapy, or death during the 3 years. The levels of the urinary SH3YL1-to-creatinine ratio (USCR) were significantly different among the five stages of chronic kidney disease (CKD) and the three groups, based on albuminuria levels. The USCR levels showed a significant negative correlation with eGFR and a positive correlation with the urinary albumin-to-creatinine ratio (UACR). Plasma SH3YL1 levels were significantly correlated with UACR. The highest tertile group of USCR and plasma SH3YL1 had a significantly lower probability of renal event-free survival. Furthermore, the highest tertile group of USCR showed a significant association with the incidence of renal events after full adjustment: adjusted hazard ratio (4.636: 95% confidence interval, 1.416–15.181, p = 0.011). This study suggests that SH3YL1 is a new diagnostic biomarker for renal outcomes in patients with type 2 diabetes.
format Online
Article
Text
id pubmed-10141384
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101413842023-04-29 SH3YL1 Protein Predicts Renal Outcomes in Patients with Type 2 Diabetes Han, Sang Youb Han, Seung Hyun Ghee, Jung Yeon Cha, Jin Joo Kang, Young Sun Cha, Dae Ryong Life (Basel) Article NADPH oxidase (NOX)-derived oxidative stress is an important factor in renal progression, with NOX4 being the predominant NOX in the kidney. Recently, Src homology 3 (SH3) domain-containing YSC84-like 1 (SH3YL1) was reported to be a regulator of NOX4. In this study, we tested whether the SH3YL1 protein could predict 3-year renal outcomes in patients with type 2 diabetes. A total of 131 patients with type 2 diabetes were enrolled in this study. Renal events were defined as a 15% decline in the estimated glomerular filtration rate (eGFR) from the baseline, the initiation of renal replacement therapy, or death during the 3 years. The levels of the urinary SH3YL1-to-creatinine ratio (USCR) were significantly different among the five stages of chronic kidney disease (CKD) and the three groups, based on albuminuria levels. The USCR levels showed a significant negative correlation with eGFR and a positive correlation with the urinary albumin-to-creatinine ratio (UACR). Plasma SH3YL1 levels were significantly correlated with UACR. The highest tertile group of USCR and plasma SH3YL1 had a significantly lower probability of renal event-free survival. Furthermore, the highest tertile group of USCR showed a significant association with the incidence of renal events after full adjustment: adjusted hazard ratio (4.636: 95% confidence interval, 1.416–15.181, p = 0.011). This study suggests that SH3YL1 is a new diagnostic biomarker for renal outcomes in patients with type 2 diabetes. MDPI 2023-04-07 /pmc/articles/PMC10141384/ /pubmed/37109492 http://dx.doi.org/10.3390/life13040963 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Han, Sang Youb
Han, Seung Hyun
Ghee, Jung Yeon
Cha, Jin Joo
Kang, Young Sun
Cha, Dae Ryong
SH3YL1 Protein Predicts Renal Outcomes in Patients with Type 2 Diabetes
title SH3YL1 Protein Predicts Renal Outcomes in Patients with Type 2 Diabetes
title_full SH3YL1 Protein Predicts Renal Outcomes in Patients with Type 2 Diabetes
title_fullStr SH3YL1 Protein Predicts Renal Outcomes in Patients with Type 2 Diabetes
title_full_unstemmed SH3YL1 Protein Predicts Renal Outcomes in Patients with Type 2 Diabetes
title_short SH3YL1 Protein Predicts Renal Outcomes in Patients with Type 2 Diabetes
title_sort sh3yl1 protein predicts renal outcomes in patients with type 2 diabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141384/
https://www.ncbi.nlm.nih.gov/pubmed/37109492
http://dx.doi.org/10.3390/life13040963
work_keys_str_mv AT hansangyoub sh3yl1proteinpredictsrenaloutcomesinpatientswithtype2diabetes
AT hanseunghyun sh3yl1proteinpredictsrenaloutcomesinpatientswithtype2diabetes
AT gheejungyeon sh3yl1proteinpredictsrenaloutcomesinpatientswithtype2diabetes
AT chajinjoo sh3yl1proteinpredictsrenaloutcomesinpatientswithtype2diabetes
AT kangyoungsun sh3yl1proteinpredictsrenaloutcomesinpatientswithtype2diabetes
AT chadaeryong sh3yl1proteinpredictsrenaloutcomesinpatientswithtype2diabetes